Global investigative sites recognize Parexel’s commitment to strong site relationships and patients
Mumbai, October 01, 2024 – Parexel, one of the world’s largest clinical research organizations (CROs) providing the full range of Phase I to IV clinical development services, today announced it has been awarded the 2024 Society for Clinical Research Sites (SCRS) Eagle Award in the CRO category for the second consecutive year. This prestigious award, presented at the annual SCRS Global Site Solutions Summit held Sept. 27-29 in Hollywood, Fla., underscores Parexel’s dedication to fostering strong partnerships with investigative sites and advancing patient-guided clinical research.
“This recognition reaffirms our commitment to collaborating with sites, which is crucial for accelerating drug development and ultimately benefiting patients,” said Teri Karcher, PhD, Chief Drug Development Officer & Executive Vice President, Head of Launch Excellence at Parexel. “Receiving this award two years in a row is a reflection of the efforts and innovative spirit of our global site-facing and site-supporting teams.”
Parexel’s success in cultivating meaningful relationships with investigative sites is largely attributed to its expansive Site Alliance Network, comprising our top performing sites and 21,000 global site investigators. The company’s proactive approach to reducing site burden and enhancing the patient experience has been pivotal in delivering cutting-edge therapies to patients worldwide.
